Richard G. Langley MD
Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
Richard Langley is Professor and Director of Research in the Division of Dermatology, Department of Medicine at Dalhousie University in Canada, and was President of the Canadian Dermatology Association in 2014.
Dr Langley received his undergraduate degree at Dalhousie University, internship in internal medicine, and fellowship in dermatologic surgery at the University of Toronto, Canada, and completed his fellowship training at Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Following his training, Dr Langley joined the Faculty of Medicine at Harvard Medical School, and was Director of Clinical Investigations Unit at Massachusetts General Hospital until June 2000.
Dr Langley has authored over 175 articles, book chapters, and other publications and he is a regular reviewer for several medical and dermatology journals. He is a principal investigator and has conducted over 150 Phase 1–3 studies involving most of the biologic agents in psoriasis and new immunotherapies in atopic dermatitis. He also has an imaging laboratory that has helped pioneer the application of diagnostic in vivo confocal microscopy in benign and malignant melanocytic lesions.
Principal investigator, advisory board or speaker: AbbVie, Amgen, Celgene, Janssen, LEO Pharma, Lilly, Merck, Novartis, Pfizer
The views expressed here are those of the contributors and do not reflect those of either FIDE or The Fishawack Group of Companies. The content has been developed for specialist dermatologists only. It is intended to help them with their own professional development and research and should not be relied upon for making individual clinical decisions, which are the responsibility of the treating clinicians.
Participation by Dr Richard Langley in this activity does not constitute or imply endorsement by Dalhousie University.
Latest Articles by Richard G. Langley
- December 14th 2016
- October 02nd 2016
- September 30th 2016
- September 24th 2016